|
|
- The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
- In a short-term perspective, the company has interesting fundamentals.
|
|
|
- The group's high margin levels account for strong profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The tendency within the weekly time frame is positive above the technical support level at 88.71 USD
|
|
|
- Stock prices approach a strong long-term resistance in weekly data at USD 114.42.
- The group usually releases earnings worse than estimated.
- With an enterprise value anticipated at 5.98 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company benefits from high valuations in earnings multiples.
|
|
|
|
|
| Sector Medical Equipment, Supplies & Distribution - NEC |
|
| | 1st jan. | Capitalisation (M$) | Investor Rating |
 |
 | ABBOTT LABORATORIES | 1.65% | 190 701 | |
| |
|
|
|
|
United to give travelers free COVID-19 tests on select Newark-London flights |
| Sales 2020 |
33 853 M
-
-
|
| Net income 2020 |
4 415 M
-
-
|
| Net Debt 2020 |
11 794 M
-
-
|
| P/E ratio 2020 |
45,4x |
| Yield 2020 |
1,29% |
|
| Capitalization |
191 B
191 B
-
|
| EV / Sales 2020 |
5,98x |
| EV / Sales 2021 |
5,21x |
| Nbr of Employees |
107 000 |
| Free-Float |
88,9% |
|
Upcoming event on ABBOTT LABORATORIES
Notations Surperformance© Fundamental ratings
|
Overall rating |
| Trading Rating |
|
| Investor Rating |
|
| Growth (Revenue) |
|
| Valuation |
|
| Finances |
|
| Profitability |
|
| Earnings quality |
|
| Business Predictability |
|
| P/E ratio |
|
| Potential |
|
| Yield |
|
| Consensus |
|
| 7 days EPS revision |
|
| 4 months EPS revision |
|
| 1 year EPS revision |
|
| 4 months Revenue revision |
|
| 1 year Revenue revision |
|
Technical ratings
| Short Term Timing |
|
| Middle Term Timing |
|
| Long Term Timing |
|
| RSI |
|
| Bollinger Spread |
|
| Unusual Volumes |
|
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
